Cargando…
Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study
Chronic lymphocytic leukemia (CLL), the most common leukemia worldwide, is associated with increased COVID-19 mortality. Previous studies suggest only a portion of vaccinated CLL patients develop severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antibodies. Whether the elicited anti...
Autores principales: | Haydu, J. Erika, Maron, Jenny S., Redd, Robert A., Gallagher, Kathleen M. E., Fischinger, Stephanie, Barnes, Jeffrey A., Hochberg, Ephraim P., Johnson, P. Connor, Takvorian, R. W., Katsis, Katelin, Portman, Daneal, Ruiters, Jade, Sechio, Sidney, Devlin, Mary, Regan, Connor, Blumenthal, Kimberly G., Banerji, Aleena, Judd, Allen D., Scorsune, Krista J., McGree, Brianne M., Sherburne, Maryanne M., Lynch, Julia M., Weitzman, James I., Lei, Matthew, Kotton, Camille N., Dighe, Anand S., Maus, Marcela V., Alter, Galit, Abramson, Jeremy S., Soumerai, Jacob D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789382/ https://www.ncbi.nlm.nih.gov/pubmed/35073571 http://dx.doi.org/10.1182/bloodadvances.2021006627 |
Ejemplares similares
-
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation
por: Merryman, Reid W., et al.
Publicado: (2022) -
Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis
por: Hamadani, Mehdi, et al.
Publicado: (2022) -
Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma
por: Burack, W. Richard, et al.
Publicado: (2023) -
Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study
por: Tun, Aung M., et al.
Publicado: (2022) -
Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies
por: Thomalla, D., et al.
Publicado: (2022)